Surovatamig
Based on 1 Customer Validation
Surovatamig (AZD0486; TNB-486) is a fully human anti-CD19/CD3 IgG4 bispecific antibody. Surovatamig triggers T cell activation, releases cytotoxic granules, and induces T cell-dependent cellular cytotoxicity and tumor cell lysis. Surovatamig can reduces release of pro-inflammatory cytokines including IL-2, IFNγ, TNF. Surovatamig can be used for the research of cancer, such as B cell non-Hodgkin lymphoma.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- Purity: 99.89%
- CAS No.: 2892667-02-4
- 분자량:110.46 kDa
-
보관:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- 순도&문서
- References
-
Help & FAQs
Biological Activity
half-G4-kappa_VH-h-CH2-CH3
Human
CD3D & CD3E & CD19
Surovatamig specifically binds to CD19+ human B cell lines with an EC50 range of 1.2-5.2 nM and a cell surface Kd of 1.8 nM on Nalm6 cells[1].
Surovatamig (24 h) activates human CD4+ and CD8+ T cells in the presence of CD19+ RI-1 tumor cells, with EC50 values of 103.6 pM and 121.8 pM, respectively[1].
Surovatamig (5 day) induces proliferation of human CD4+ and CD8+ T cells in the presence of CD19+ RI-1 tumor cells, with EC50 values of 62.9 pM and 46.9 pM, respectively[1].
Surovatamig (0.0001-100 nM；48 h) triggers the release of cytotoxic granules (perforin and granzyme B) from human T cells in the presence of CD19+ RI-1 tumor cells[1].
Surovatamig (24-96 h) induces time-dependent lysis of primary human B cells via T cell redirection, with >90% lysis by 96 h and an EC50 range of 0.93-1.35 nM[1].
Surovatamig (48 h) induces concentration-dependent, CD19-specific lysis of multiple human B-NHL/ALL cell lines via both CD4+ and CD8+ T cell redirection, with EC50 values of 23.5 ± 11.5 pM (Raji) and 0.9 ± 0.2 nM (RI-1)[1].
Surovatamig (48 h) induces potent CD19-specific tumor cell lysis with significantly lower levels of proinflammatory cytokines (IL-2, IFNγ, TNF) and higher cytokine release EC50 values[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Surovatamig (1-100 μg/mouse; i.v.; every 4 days; 6 doses) induces dose-dependent tumor growth inhibition in a subcutaneous diffuse large B-cell lymphoma xenograft model, with the 100 μg/mouse dose achieving 88.52% tumor growth inhibition by day 40 post-implantation[1].
Surovatamig (0.4 mg/kg) delivers potent anti-tumor activity while inducing significantly reduced CRS-associated systemic cytokine release in a humanized disseminated DLBCL xenograft model[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:CIEA-NOG (NOD.Cg-Prkdcscid IL2rgtm1Sug/JicTac) (female, 4-5 weeks old, disseminated Burkitt lymphoma xenograft via intravenous injection of 1×106 luciferase-expressing Raji cells)[1]
-
Dosage:10 ng/mouse; 100 ng/mouse; 1 μg/mouse; 10 μg/mouse
-
Administration:I.v.; every 5 days; 3 doses
-
Result:Showed dose-dependent tumor reduction relative to negative control after two treatments.
Cleared tumors to a similar extent as positive control at 100 ng, 1 μg, and 10 μg/mouse doses.
Showed tumor growth inhibition at 8 days post-implantation, but inhibition was not sustained by 14 days post-implantation at 10 ng/mouse dose.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
half-G4-kappa_VH-h-CH2-CH3
ELISA, FACS, Functional assay
-
Immobilized CD19 Protein, Human (HEK293, His, HY-P74330) can bind Surovatamig. The EC50 for this effect is 893.5 ng/mL. -
Immobilized CD3D-CD3E Heterodimer Protein, Human (Biotinylated, HEK293, His, HY-P700677) can bind Surovatamig. The EC50 for this effect is 909.9 ng/mL. -
Flow cytometric analysis of 1X106 Juakat cells with Surovatamig (HY-P991028, red). Cells were fixed with 4% paraformaldehyde. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. AF 488-conjugated AffiniPure Goat Anti-Human IgG H&L (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG4 (S228P) kappa (HY-P99003, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).
Chemical Information
-
CAS No. 2892667-02-4
-
Appearance Liquid
-
분자량 110.46 kDa
-
Color Colorless to light yellow
-
SMILES
[Surovatamig]
-
Synonyms
AZD0486; TNB-486
-
선적
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
보관
Please store the product under the recommended conditions in the Certificate of Analysis.
순도&문서
-
Data Sheet (262 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Surovatamig Related Classifications
HY-P991028 Related Classifications
Powered by Bioz